

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FILED VIA THE ELECTRONIC FILING SYSTEM, ON:

January 8, 2009

/Anita J. Galo/

January 8, 2009

SIGNATURE

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zee UPTON et al.
Serial No. : 10/565,616
Filing Date : June 9, 2006
For : SKIN REGENERATION SYSTEM
Confirmation No. : 2998
Group Art Unit : 1632
Examiner : Magdalene K. Sgagias
Attorney Docket : FAK-8011

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

1. Pursuant to 37 CFR §1.97 and §1.98, and in compliance with CFR §1.56, the Office's attention is directed to the patents, pending applications, publications and other information listed on the attached PTO-1449. Applicant(s) make no admission that the documents are prior art to the present invention.
2. Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a corresponding U.S. Patent is enclosed, or an English abstract, or a concise explanation of the relevance of the document is set forth on an attached sheet.
3. Pursuant to 37 CFR §1.97(b) this Statement is being filed (one must be checked):
 - (a) ☐ Within three months of the filing date or date of entry into the National Stage.
 - (b) ☐ Before the mailing date of a first Office Action on the merits.

- (c) ☒ After the period set forth in 37 CFR §1.97(b) but before the mailing date of either a final action or a notice of allowance or an action that otherwise closes prosecution in the application.
- 1) ☐ A certification is given below,
 - 2) ☐ Enclosed is a check covering the fee (\$180.00) set forth in §1.17(p) for consideration of this Statement, or
 - 3) ☐ Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.
 - 4) ☒ Charge the fee set forth in 37 CFR §1.17(p) to the Credit Card as shown on the attached Credit Card information authorization form PTO-2038.

- (d) ☐ After the mailing date of either a final action or a notice of allowance, but before payment of the issue fee. The required certification and fee is indicated below.
- 1) ☐ Enclosed is a check covering the fee set forth in 37 CFR §1.17(p) \$180, or
 - 2) ☐ Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.
 - 3) ☐ Charge the fee set forth in 37 CFR §1.17(p) to the Credit Card as shown on the attached Credit Card information authorization form PTO-2038.

4. Certification (if applicable):

- (a) ☐ The undersigned hereby certifies that each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

- (b) ☐ The undersigned hereby certifies that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the undersigned's knowledge after making reasonable inquiry no item of information contained in the Statement, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Statement.
5. The Commissioner is hereby authorized to charge any additional fees, fees underpaid, or credit any overpayment with regard to this Statement to Deposit Account No. 20-0090.
6. Concise Explanation (if needed):
- (1) ☒ Below is a Concise Statement of Relevance of enclosed non-English language document(s).

FOREIGN PATENT DOCUMENTS

Patent No.

Relevance

PCT WO 2002/024219 A1

In English.

OTHER DOCUMENTS

Noble et al., 2003 "Insulin-Like Growth Factor-II Bound to Vitronectin Enhances MCF-7 Breast Cancer Cell Migration", *Endocrinology*, 144:2417-2424.

Krickler et al. 2003 "Structural and Functional Evidence for the Interaction of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins with Vitronectin", *Endocrinology*, 144:2807-2815.

Tsuboi et al. 1992 "Stimulation of Keratinocyte Migration by Growth Factors", *The Journal of Dermatology*, 19:652-653.

O'Keefe et al. 1988 "Stimulation of Growth of Keratinocytes by Basic Fibroblast Growth Factor", *J. Invest. Dermatol.*, 90:767-769.

Ando et al. 1993 "Epidermal Growth Factor and Insulin-Like Growth Factor I Enhance Keratinocyte Migration", *J. Invest. Dermatol.*, 100:633-639.

Bhora et al., 1995, "Effect of Growth Factors on Cell Proliferation and Epithelialization in Human Skin", *J. Surg. Res.* 59:236-244.

Krane et al., 1991, "Synergistic Effects of Epidermal Growth Factor (EGF) and Insulin-Like Growth Factor I/Somatostatin C. (IGF-I) on Keratinocyte Proliferation May Be Mediated by IGF-I Transmodulation of the EGF Receptor", *J. Invest. Dermatol.*, 96:419-424.

OTHER DOCUMENTS

Nam et al., 2002, "Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions", *Endocrinology*, 143:30-36.

Schleicher et al., 2005, "Surface Modification by Complexes of Vitronectin and Growth Factors for Serum-Free Culture of Human Osteoblasts", *Tissue Engineering*, 11:1688-1698.

Warwick et al., 2002, "The Co-Application of Sprayed Cultured Autologous Keratinocytes and Autologous Fibrin Sealant in a Porcine Wound Model", *British Journal of Plastic Surgery*, 55:219-227.

Nagano et al., 1992, "Yolk Vitronectin", *The Journal of Biological Chemistry*, 267:24863-24870.

Seger et al., 1998, "Phosphorylation of Vitronectin by Casein Kinase II", *The Journal of Biological Chemistry*, 273:24805-24813.

Respectfully submitted,

/Richard S. Wesorick/

Richard S. Wesorick
Reg. No. 40,871

TAROLLI, SUNDHEIM, COVELL,
& TUMMINO L.L.P.
1300 East Ninth Street, Suite 1700
Cleveland, OH 44114
Phone: (216) 621-2234
Fax: (216) 621-4072
Customer No.: 26,294